Jamshedpur Reporter

Essential Tremor Pipeline Analysis 2024 | Clinical Trials, Latest Approvals, Treatment Outlook, Therapies, Key Companies | Merz Pharma, SAGE Therapeutics, GE Healthcare, Praxis Precision Medicines, OB

 Breaking News
  • No posts were found

Essential Tremor Pipeline Analysis 2024 | Clinical Trials, Latest Approvals, Treatment Outlook, Therapies, Key Companies | Merz Pharma, SAGE Therapeutics, GE Healthcare, Praxis Precision Medicines, OB

June 17
18:25 2024
Essential Tremor Pipeline Analysis 2024 | Clinical Trials, Latest Approvals, Treatment Outlook, Therapies, Key Companies | Merz Pharma, SAGE Therapeutics, GE Healthcare, Praxis Precision Medicines, OB
Essential Tremor Pipeline Analysis 2024
“Essential Tremor Pipeline Insight, 2024” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Essential Tremor Market.

DelveInsight’s “Essential Tremor Pipeline Insight 2024,” report provides comprehensive insights about 7+ companies and 10+ pipeline drugs in the Essential Tremor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

The Essential Tremor Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Essential Tremor Overview

Essential tremor is a chronic, progressive neurological condition characterized by a 4–12-Hz kinetic tremor. This tremor occurs during voluntary movements such as writing or eating and primarily affects the hands and arms, but can eventually extend to involve other parts of the body including the head (neck), voice, jaw, and other regions.

Due to variability in causes, clinical presentation, response to medication, and pathological findings, there is growing support for the idea that ET may represent a spectrum of diseases united by the common feature of kinetic tremor in the arms. Therefore, it may be more fitting to refer to these conditions collectively as “the essential tremors.

Essential Tremor Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for the treatment of Essential Tremor and the aggregate therapies developed by major pharma companies.

  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Essential Tremor market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Request for a detailed sample report @ https://www.delveinsight.com/sample-request/essential-tremor-pipeline-insight

Analysis of Emerging Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Route of Administration

Essential tremor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Intranasal

  • Intrathecal

  • Intravenous

  • Oral

  • Oral/Intravenous

  • Parenteral

  • Subcutaneous

  • Subcutaneous/Intramuscular

  • Transdermal

  • Molecule Type

The report covers the pipeline products that have been categorized under various Molecule types, such as

  • Antisense oligonucleotide

  • Gene therapy

  • Hormones

  • Neuropeptides

  • Oligonucleotides

  • Small Molecule

  • Triglyceride

Learn How the Ongoing Clinical & Commercial Activities will Affect the Essential Tremor Therapeutic Segment @ https://www.delveinsight.com/sample-request/essential-tremor-pipeline-insight

Essential Tremor Therapeutics Landscape

Key companies such as Sage therapeutics are leading the essential tremor therapeutics market with its Essential tremor drug candidates in the most advanced stage of clinical development.

The Leading Companies in the Essential Tremor Therapeutics Market Include:

  • Merz Pharma

  • SAGE Therapeutics

  • GE Healthcare

  • Praxis Precision Medicines

  • OB Pharmaceuticals

  • Novartis

  • Jazz Pharmaceuticals

Essential Tremor Drugs Profile:

SAGE-324: Sage Therapeutics

SAGE-324 is a new oral investigational drug categorized as a neuroactive steroid (NAS) and a positive allosteric modulator (PAM) of GABAA receptors. NAS GABAA receptor PAMs interact with both synaptic and extrasynaptic GABAA receptors, thereby enhancing the inhibitory effects of the GABAergic system, which is crucial for regulating neuronal activity in the brain. GABA serves as the principal inhibitory neurotransmitter in the central nervous system and is essential for maintaining balanced neuronal function. Dysregulation of GABA has been implicated in the pathophysiology of ET. SAGE-324 is currently undergoing Phase II development trials.

Table of Contents

1. Report Introduction

2. Executive Summary

3. Essential Tremor Current Treatment Patterns

4. Essential Tremor – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Essential Tremor Late Stage Products (Phase-III)

7. Essential Tremor Mid-Stage Products (Phase-II)

8. Essential Tremor Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Essential Tremor Discontinued Products

13. Essential Tremor Product Profiles

14. Key Companies in the Essential Tremor Market

15. Key Products in the Essential Tremor Therapeutics Segment

16. Dormant and Discontinued Products

17. Essential Tremor Unmet Needs

18. Essential Tremor Future Perspectives

19. Essential Tremor Analyst Review  

20. Appendix

21. Report Methodology

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/